Ocugen, Inc. - Common Stock (NQ:OCGN)

1.020 +0.020 (+2.00%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ocugen, Inc. - Common Stock

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

36 37 Next >

Ocugen-Partnered Covaxin's WHO Clearance Delayed Further Over Queries: Sources ↗

September 27, 2021

The World Health Organization (WHO) has further delayed the emergency use authorization (EUA) for Covaxin, a COVID-19 vaccine developed in India. Ocugen Inc (NASDAQ:...

Via Benzinga

Is Ocugen Worth Another Look After Good News for COVID Vaccine Covaxin? ↗

September 24, 2021

An anticipated emergency use listing for the vaccine won't help Ocugen.

Via The Motley Fool

Ocugen's India-Based Partner Concludes COVID-19 Vaccine Trials In Children: Report ↗

September 21, 2021

India-based Bharat Biotech has completed the Phase 2 and 3 trials of COVID-19 vaccine, Covaxin, for use in 2 to 18 years. Ocugen Inc (NASDAQ: OCGN...

Via Benzinga

It’s OK to Sell the News on Ocugen and Covaxin ↗

September 20, 2021

OCGN stock jumped when Covaxin received WHO approval. But with two major obstacles in the way of U,S. approval, you should sell the news.

Via InvestorPlace

Could This News Spark a Turnaround for Ocugen? ↗

September 19, 2021

Ocugen shares soared more than 700% early in the year. They've since lost half of the gain.

Via The Motley Fool

Why COVID Vaccine Stocks BioNTech, Moderna, and Novavax Are Sliding While Ocugen Is Rising ↗

September 17, 2021

Investors are nervous about a Food and Drug Administration advisory panel meeting and optimistic about a World Health Organization decision.

Via The Motley Fool

I’d Take Nio Stock’s 12-Month Double Despite Falling Below $50 ↗

September 17, 2021

A $10,000 investment in NIO stock a year ago is worth more than $20,000 today. From here, under $40 remains a great entry point if you want to make money over the long haul.

Via InvestorPlace

Topics Electric Vehicles

WHO Approval Should Get Ocugen Stock Over the $15 Barrier ↗

September 16, 2021

Sharp up-and-down moves in OCGN stock shouldn't scare investors away, as a regulator's nod for Covaxin should put the stock back on track.

Via InvestorPlace

Here’s What the Charts Say About Ocugen Stock Now ↗

September 15, 2021

Ocugen is a high-risk, high-reward speculative play. The charts for OCGN stock show some promise, but here's the level it has to hold above.

Via InvestorPlace

OCGN Stock: Why Ocugen Shares Are Shooting Higher Today ↗

September 13, 2021

The WHO could be about to green light a vaccine from one of Ocugen's partners, but that doesn't mean OCGN stock will stay in the green.

Via InvestorPlace

72 Biggest Movers From Yesterday ↗

September 14, 2021

Gainers aTyr Pharma, Inc. (NASDAQ: LIFE) jumped 67% to settle at $9.15 on Monday as the company announced positive results from its Phase 1b/2a trial evaluating its lead...

Via Benzinga

Where's Ocugen Stock Headed Monday And Why? ↗

September 13, 2021

Ocugen Inc. (NASDAQ: OCGN) shares were trading higher Monday, after Bharat Biotech: a company partner, was given the nod for a COVID-19 vaccine by the World Health Organization....

Via Benzinga

Here's Why Ocugen Is Skyrocketing Today ↗

September 13, 2021

There's both good and bad news for this troubled coronavirus vaccine biotech.

Via The Motley Fool

OCGN Stock: What Ocugen Investors Are Saying as Shares Surge Today ↗

September 13, 2021

Ocugen (OCGN) stock is on the move today as traders on social media push the company higher in a new rally for the shares.

Via InvestorPlace

Why Are Ocugen Shares Surging On Monday? ↗

September 13, 2021

According to sources, the World Health Organization (WHO) is likely to grant India's COVID-19 vaccine, Covaxin, for an emergency use listing (EUL) this week. Ocugen Inc...

Via Benzinga

45 Stocks Moving In Monday's Mid-Day Session ↗

September 13, 2021

Gainers Aterian, Inc. (NASDAQ: ATER) jumped 54.1% to $18.18. Investor presentation released on Friday is now circulating on news outlets. Itamar Medical Ltd. (NASDAQ: ITMR)...

Via Benzinga

OCUGEN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Ocugen, Inc. - OCGN

September 10, 2021

From Kahn Swick & Foti, LLC

Via Business Wire

Vaxart Stock Is One Vaccine Also-Ran Worth Another Look ↗

September 08, 2021

The jury's out whether its oral Covid-19 vaccine will be successful, but VXRT stock may still be worth it as a speculative play.

Via InvestorPlace

This 28% Short Biotech Company Has A Better 1-Year Return Than AMC, Snap, Apple And Tesla ↗

September 07, 2021

An investment in Ocugen Inc (NASDAQ: OCGN) one year ago is undoubtedly a sight for sore eyes. Since January 2021, Ocugen stock's year-to-date return has outperformed a number...

Via Benzinga

Ocugen Should Hit $9 If Its Covid-19 Vaccine Gets Approved ↗

September 01, 2021

There's no revenue yet for Ocugen, but OCGN stock could be worth 19% higher if its Covid-19 vaccine gets the thumbs up.

Via InvestorPlace

Ocugen Stock Will Suffer Its Inevitable Demise Sooner Rather Than Later ↗

September 01, 2021

At some point, the music will stop for OCGN stock, but for now, there's still plenty at play to keep it at inflated prices.

Via InvestorPlace

Ocugen Stock Seems Unattractive With Regulatory Uncertainties ↗

August 31, 2021

OCGN stock is unattractive as regulatory approval delays have limited the revenue and cash flow potential for the Covid-19 vaccine.

Via InvestorPlace

Ocugen Stock Doesn’t Have Short-Term Catalysts Needed To Make It a Buy ↗

August 30, 2021

OCGN stock is interesting once again as concerns regarding the Delta variant mount. But that should not be your sole reason to invest in Ocugen.

Via InvestorPlace

Atossa Therapeutics May Look Tempting, but There’s No Reason to Get in Now ↗

August 30, 2021

ATOS stock has some exciting points, but its story sends a message investors have heard, namely the price of progress is dilution.

Via InvestorPlace

The Odds Are Firmly Against Ocugen Stock Now ↗

August 27, 2021

OCGN stock is a remarkably risky Covid-19 vaccine play, as the company faces a myriad of regulatory roadblocks on different fronts.

Via InvestorPlace

August 25, 2021

Not every stock on the popular trading app is worth owning.

Via The Motley Fool

Vaccine Victory ↗

August 24, 2021

Monday the US stock market moved into further robust mode fueled by official FDA approval of the Pfizer and BioNTech COVID-19 vaccines. Will the momentum last through to Thursday when the Fed's Jackson...

Via Talk Markets

Topics Economy

Cynicism and Conspiracy Theories Could Help Ocugen ↗

August 24, 2021

While OCGN stock seems well behind the vaccination race to be worth a shot, there is one narrative that could potentially help.

Via InvestorPlace

Now That The FDA Approved Pfizer-BioNTech, Is This It For Vaccine Stocks? ↗

August 23, 2021

If there's one thing to take away from any conversation about biotech stocks, it's that any company with their hat in the ring is likely making a version of something they hope to be better than the...

Via Talk Markets

Ocugen’s Facing a Major Uphill Climb Without FDA Approval ↗

August 23, 2021

OCGN stock will be hard pressed to push any higher in the absence of good news

Via InvestorPlace

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.